Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.

Tsaur I, Thomas A, Taskiran E, Rutz J, Chun FK, Haferkamp A, Juengel E, Blaheta RA

Open source

DOI
10.3390/cancers14194643
Published
2022 Sep 24
Container
Cancers
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers14194643,
  title = {Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.},
  author = {Tsaur I and Thomas A and Taskiran E and Rutz J and Chun FK and Haferkamp A and Juengel E and Blaheta RA},
  year = {2022},
  journal = {Cancers},
  doi = {10.3390/cancers14194643},
  url = {https://doi.org/10.3390/cancers14194643}
}

RIS

TY  - JOUR
TI  - Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.
AU  - Tsaur I
AU  - Thomas A
AU  - Taskiran E
AU  - Rutz J
AU  - Chun FK
AU  - Haferkamp A
AU  - Juengel E
AU  - Blaheta RA
PY  - 2022
JO  - Cancers
DO  - 10.3390/cancers14194643
UR  - https://doi.org/10.3390/cancers14194643
ER  - 

APA

I, T., A, T., E, T., J, R., FK, C., A, H., E, J., & RA, B. (2022). Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.. Cancers. https://doi.org/10.3390/cancers14194643

Source records